Search

Displaying results 9191 - 9200 of 10000 in total
  1. Drug

    Metformin C-11

    go.drugbank.com/drugs/DB15181
    Experimental

    Metformin c-11 is under investigation in clinical trial NCT03122769 (Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography).

  2. Drug

    Uliledlimab

    go.drugbank.com/drugs/DB16675
    Investigational

    Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).

  3. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

  4. Drug

    ALLO-605

    go.drugbank.com/drugs/DB18641
    Investigational

    ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).

  5. Drug

    RC88

    go.drugbank.com/drugs/DB18697
    Experimental

    RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).

  6. Drug

    TBI-223

    go.drugbank.com/drugs/DB18911
    Investigational

    TBI-223 is under investigation in clinical trial NCT06192160 (Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis).

    Synonyms: CARBAMIC ACID, N-(((5S)-3-(3-FLUORO-4-(2-OXA-6-AZASPIRO(3.3)HEPT-6-YL)PHENYL)-2-OXO-5-OXAZOLIDINYL)METHYL)-, METHYL ESTER
  7. Drug

    Rovadicitinib

    go.drugbank.com/drugs/DB21747
    Investigational

    Rovadicitinib is under investigation in clinical trials NCT06682169 and NCT06300320 for the treatment of Chronic Graft-versus-host Disease.

  8. Drug

    Coagulation factor XIa

    go.drugbank.com/drugs/DB15420
    Investigational

    Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).

  9. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  10. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]